CRISPR Therapeutics AG has disclosed important transactions involving its common shares by director George Simeon. The recent filing indicates a mix of acquisitions and disposals, shedding light on the company's internal dynamics and potential market strategies.
CRISPR Therapeutics AG, classified under the SIC code 2836, specializes in biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker CRSP. As a large accelerated filer, CRISPR has been actively engaging in various financial activities, as evidenced by its recent filings.
In the filing dated October 16, 2026, Simeon reported the acquisition of 30,000 shares at a price of $14 per share on October 14, 2026. Additionally, he disposed of 14,514 shares at a weighted average price of approximately $49.63, with the sales executed under a Rule 10b5-1 trading plan established in December 2025. Following these transactions, Simeon holds a total of 69,687 shares directly.
These transactions may affect investor sentiment and the company's stock performance. The filing highlights the ongoing strategic maneuvers within CRISPR Therapeutics, reflecting the competitive landscape of the biological products sector.
Looking ahead, it remains unclear what specific actions CRISPR Therapeutics will take next, as the filing does not provide further details on upcoming plans or additional filings.